Back to top
more

Medpace (MEDP)

(Real Time Quote from BATS)

$392.26 USD

392.26
30,585

+5.92 (1.53%)

Updated Jun 3, 2024 10:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System

by Zacks Equity Research

SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.

Here's Why You Should Retain Abbott (ABT) Stock For Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Bio Rad (BIO) Grows Internationally on New Product Launches

by Zacks Equity Research

Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.

CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies

by Zacks Equity Research

CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.

Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Smith+Nephew (SNN) Rolls Out Robotic Assisted Surgical System

by Zacks Equity Research

Smith+Nephew's (SNN) CORI system enables each patient to have a knee replacement that is shape-matched and aligned to their specific anatomy.

Urmimala Biswas headshot

Medtronic's (MDT) Q2 Earnings Beat, Revenues Lag Estimates

by Urmimala Biswas

Medtronic (MDT) cuts revenue growth guidance for the full year on the projection of a severe pandemic impact to continue through the rest of the year.

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

by Zacks Equity Research

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Illumina's (ILMN) New Alliance to Accelerate Genomics in China

by Zacks Equity Research

Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Veeva Systems (VEEV) Digital Tools Boost Patient Engagement

by Zacks Equity Research

Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.

Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic

by Zacks Equity Research

The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).

CVS Health's (CVS) New Measures to Boost Omnichannel Health

by Zacks Equity Research

CVS Health's (CVS) new measures will support its strategy of making health care more affordable, accessible and convenient for consumers.

Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic

by Zacks Equity Research

Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.

Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes

by Zacks Equity Research

Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.

Thermo Fisher (TMO) New Facility to Advance Lab Products Supply

by Zacks Equity Research

Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.

Bruker (BRKR) Advances in Proteomics Workflow With New Pacts

by Zacks Equity Research

Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.

Illumina (ILMN) iHope Genetic Health Program Expands WGS Access

by Zacks Equity Research

Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.

NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical

by Zacks Equity Research

NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.

Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance

by Zacks Equity Research

Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.